Glaukos Sales Surge 38% to $133.5M, Net Loss Narrows to $16.2M

Ticker: GKOS · Form: 10-Q · Filed: Oct 31, 2025 · CIK: 1192448

Sentiment: mixed

Topics: Ophthalmology, Medical Devices, Pharmaceuticals, Glaucoma Treatment, Corneal Disorders, Revenue Growth, Net Loss

TL;DR

**Glaukos is burning cash but revenue growth is strong, making it a speculative buy for long-term growth in ophthalmic tech.**

AI Summary

GLAUKOS Corp (GKOS) reported a significant increase in net sales for the three months ended September 30, 2025, reaching $133.5 million, up 38.1% from $96.7 million in the same period last year. For the nine months ended September 30, 2025, net sales grew to $364.3 million, a 31.1% increase from $278.0 million in 2024. Despite revenue growth, the company continues to operate at a loss, with a net loss of $16.2 million for the quarter, an improvement from a $21.4 million net loss in Q3 2024. The nine-month net loss also narrowed to $54.0 million from $112.8 million in the prior year. Gross profit increased to $104.7 million for the quarter, up from $74.1 million, reflecting improved operational efficiency. Key business changes include the controlled commercial launch activities for iDose TR in 2024, a novel dropless platform therapy. Risks highlighted include the potential failure to achieve commercial success of iDose TR or Epioxa, and the impact of general economic conditions and supply chain disruptions. The strategic outlook focuses on developing novel dropless platform therapies and commercializing products for glaucoma, corneal disorders, and retinal diseases.

Why It Matters

This 10-Q reveals Glaukos is successfully scaling revenue, with a 38.1% quarterly sales jump, indicating strong market adoption for its ophthalmic products, particularly with the iDose TR launch. For investors, the narrowing net loss from $21.4 million to $16.2 million suggests a path towards profitability, making GKOS a more attractive growth play in the competitive medical technology sector. Employees benefit from a growing company with expanding product lines, while customers gain access to innovative treatments for glaucoma and corneal disorders. This performance positions Glaukos to challenge larger players by advancing the standard of care in ophthalmology.

Risk Assessment

Risk Level: medium — The company reported a net loss of $16.2 million for the quarter and $54.0 million for the nine months ended September 30, 2025, indicating it is not yet profitable. Cash and cash equivalents decreased significantly from $169.6 million at December 31, 2024, to $98.2 million at September 30, 2025, and net cash used in operating activities was $21.6 million for the nine months, highlighting ongoing cash burn.

Analyst Insight

Investors should monitor Glaukos's continued revenue growth and progress towards profitability, especially the commercial success of iDose TR. Consider holding if already invested, but new investors should approach with caution due to ongoing losses and cash burn, balancing the strong sales growth against the financial risks.

Financial Highlights

revenue
$133.5M
operating Margin
-12.3%
total Assets
$999.4M
total Debt
$155.9M
net Income
-$16.2M
eps
-$0.28
gross Margin
78.4%
cash Position
$98.2M
revenue Growth
+38.1%

Revenue Breakdown

SegmentRevenueGrowth
Total Net Sales$133.5M+38.1%
Total Net Sales$364.3M+31.1%

Key Numbers

Key Players & Entities

FAQ

What were GLAUKOS Corp's net sales for the third quarter of 2025?

GLAUKOS Corp reported net sales of $133,537 thousand for the three months ended September 30, 2025, a significant increase from $96,670 thousand in the same period of 2024.

Did GLAUKOS Corp achieve profitability in Q3 2025?

No, GLAUKOS Corp reported a net loss of $16,231 thousand for the three months ended September 30, 2025, although this was an improvement from a net loss of $21,409 thousand in Q3 2024.

What is the status of GLAUKOS Corp's iDose TR product?

GLAUKOS Corp commenced controlled commercial launch activities for iDose TR in 2024, positioning it as a novel dropless platform therapy for glaucoma treatment.

What are the primary risks identified by GLAUKOS Corp in its 10-Q filing?

Key risks include the potential failure to achieve commercial success of iDose TR or Epioxa, downturns in general economic conditions, supply and manufacturing disruptions, and the inability to reach sustained profitability.

How much cash and cash equivalents did GLAUKOS Corp have as of September 30, 2025?

As of September 30, 2025, GLAUKOS Corp had $98,246 thousand in cash and cash equivalents, a decrease from $169,626 thousand at December 31, 2024.

What was GLAUKOS Corp's gross profit for the nine months ended September 30, 2025?

GLAUKOS Corp's gross profit for the nine months ended September 30, 2025, was $284,278 thousand, up from $212,590 thousand in the same period of 2024.

How many shares of common stock were outstanding for GLAUKOS Corp as of October 29, 2025?

As of October 29, 2025, there were 57,434,740 shares of GLAUKOS Corp's Common Stock outstanding.

What is GLAUKOS Corp's focus in terms of product development?

GLAUKOS Corp is focused on developing novel dropless platform therapies and commercializing products for glaucoma, corneal disorders (like keratoconus, dry eye, refractive vision correction), and retinal diseases (such as neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion).

What was the net cash used in operating activities for GLAUKOS Corp for the nine months ended September 30, 2025?

GLAUKOS Corp reported net cash used in operating activities of $21,632 thousand for the nine months ended September 30, 2025, a significant reduction from $61,825 thousand used in the same period of 2024.

What regulatory approvals has GLAUKOS Corp received for its products?

GLAUKOS Corp launched its first Micro-Invasive Glaucoma Surgery (MIGS) device commercially in 2012 and received United States (U.S.) Food and Drug Administration (FDA) approval in 2016 for a proprietary bio-activated pharmaceutical therapy for keratoconus.

Risk Factors

Industry Context

Glaukos operates in the specialized ophthalmic medical technology market, focusing on treatments for glaucoma, corneal disorders, and retinal diseases. The industry is characterized by innovation, significant R&D investment, and regulatory hurdles. Key trends include the development of less invasive and more effective therapies, such as dropless drug delivery systems.

Regulatory Implications

The development and commercialization of novel therapies like iDose TR and Epioxa are subject to stringent regulatory approvals from bodies like the FDA. Delays or failures in the approval process, or post-market issues, can significantly impact market entry and financial performance.

What Investors Should Do

  1. Monitor iDose TR and Epioxa commercialization progress.
  2. Analyze cash burn and funding strategy.
  3. Evaluate gross margin improvements.

Key Dates

Glossary

iDose TR
A novel dropless platform therapy developed by Glaukos for ophthalmic conditions. (Represents a key product launch and a significant driver of future revenue, but also carries commercialization risks.)
Epioxa
Another novel therapy developed by Glaukos, likely for ophthalmic disorders. (Similar to iDose TR, its commercial success is critical for the company's growth strategy.)
Accumulated deficit
The cumulative net losses of a company since its inception, less any net profits. (Glaukos has an accumulated deficit of $799.5M as of September 30, 2025, highlighting its history of unprofitability.)
Operating lease right-of-use asset
An asset recognized under accounting standards for the right to use an asset over the lease term. (Indicates the company's use of leased assets, such as property and equipment, which have associated liabilities.)

Year-Over-Year Comparison

Compared to the prior year, Glaukos has demonstrated robust revenue growth, with net sales increasing by 38.1% in Q3 2025 and 31.1% year-to-date. While the net loss has narrowed significantly from $21.4M to $16.2M for the quarter and from $112.8M to $54.0M year-to-date, the company continues to operate at a loss. Key risks remain, particularly concerning the commercial success of new products and potential supply chain disruptions, with no new major risks explicitly identified in this filing.

Filing Stats: 4,522 words · 18 min read · ~15 pages · Grade level 19 · Accepted 2025-10-30 18:53:18

Key Financial Figures

Filing Documents

: FINANCIAL INFORMATION

PART I : FINANCIAL INFORMATION 5 Item 1.

Financial Statements

Financial Statements 5 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Operations 6 Condensed Consolidated Statements of Comprehensive Loss 7 Condensed Consolidated Statements of Stockholders' Equity 8 Condensed Consolidated Statements of Cash Flows 9 Notes to Condensed Consolidated Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 26 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 39 Item 4.

Controls and Procedures

Controls and Procedures 39

: OTHER INFORMATION

PART II : OTHER INFORMATION 40 Item 1.

Legal Proceedings

Legal Proceedings 40 Item1A.

Risk Factors

Risk Factors 40 Item 5. Other Information 56 Item 6. Exhibits 56

SIGNATURES

SIGNATURES 57 2 Table of Contents Note Regarding Forward-Looking Statements This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act) All statements other than statements of historical or current facts included in this report are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Any statements in this Quarterly Report on Form 10-Q regarding future operations, including our expectations for future expenses, capital expenditures and income, our expectations regarding the impact of the macroeconomic environment, our strategy for growth, product development activities, the impact of the regulatory environment, including the timing and likelihood of regulatory approvals and the impact of new or changing regulations and pricing, and market position are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions based on the information available to management at the time of this report. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, we caution you that these forward-looking statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. You are urged to carefully review the disclosures we make concerning the risks we face and other factors that may affect the o

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements GLAUKOS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except par values) September 30, December 31, 2025 2024 (unaudited) Assets Current assets: Cash and cash equivalents $ 98,246 $ 169,626 Short-term investments 175,466 149,289 Accounts receivable, net 98,684 60,744 Inventory 63,863 57,678 Prepaid expenses and other current assets 18,509 12,455 Total current assets 454,768 449,792 Restricted cash 3,834 4,733 Property and equipment, net 110,944 97,867 Operating lease right-of-use asset 31,536 30,254 Finance lease right-of-use asset 40,007 41,816 Intangible assets, net 264,136 263,445 Goodwill 66,710 66,134 Deposits and other assets 27,443 20,715 Total assets $ 999,378 $ 974,756 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 19,883 $ 13,026 Accrued liabilities 67,633 62,099 Total current liabilities 87,516 75,125 Operating lease liability 35,847 33,936 Finance lease liability 68,468 69,463 Deferred tax liability, net 6,921 6,928 Other liabilities 31,083 22,373 Total liabilities 229,835 207,825 Commitments and contingencies (Note 13) Stockholders' equity: Preferred stock, $ 0.001 par value; 5,000 shares authorized; no shares issued and outstanding as of September 30, 2025 and December 31, 2024 - - Common stock, $ 0.001 par value; 150,000 shares authorized; 57,414 and 56,472 shares issued and 57,386 and 56,444 shares outstanding as of September 30, 2025 and December 31, 2024, respectively 57 56 Additional paid-in capital 1,566,029 1,509,831 Accumulated other comprehensive income 3,062 2,615 Accumulated deficit ( 799,473 ) ( 745,439 ) Less treasury stock ( 28 shares as of September 30, 2025 and December 31, 2024) ( 132 ) ( 132 ) Total stockholders' equity 769,543 766,931 Total liabilities and stockholders' equity $ 999,37

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing